• Acusphere Inc., of Watertown, Mass., entered definitive agreements with institutional investors to raise $23.8 million in net proceeds through the sale of shares and warrants. The company entered subscription agreements with the investors and agreed to sell a total of about 9.3 million units, each consisting of one share and one warrant to buy 0.4 shares of common stock at $3.11 per share, for a purchase price of $2.75 per unit. Cowen and Co. LLC acted as exclusive placement agent.

• Cardioxyl Pharmaceuticals Inc., of Towson, Md., secured $14.5 million in a Series A venture financing. Proceeds will be used to advance the company's nitroxyl donor program to treat acute decompensated heart failure. The round was co-led by The Aurora Funds and New Enterprise Associates.

• Cytokinetics Inc., of South San Francisco, entered definitive agreements with selected institutional investors to buy $37 million of its common stock in a registered direct offering of 5.3 million shares at $7 each - a 6 percent discount to the closing price Wednesday. Net proceeds will be about $35 million and will be used for research and development, including clinical trials, working capital and other general corporate purposes. Lazard Capital Markets LLC acted as the lead placement agent, and JMP Securities LLC and Rodman & Renshaw LLC acted as co-placement agents.

• ImmuneRegen BioSciences Inc., of Scottsdale, Ariz., a wholly owned subsidiary of IR BioSciences Holdings Inc., completed a round of private equity funding of common stock and warrants to buy common stock. The company received $5.5 million in gross proceeds at closing and expects to use the net proceeds to fund its product development efforts. Warrants issued to investors are exercisable for five years through Dec. 6, 2011. The warrants entitle the holder to buy one share for every two shares purchased in the private placement.

• MannKind Corp., of Valencia, Calif., agreed to sell an aggregate of 20 million shares of its common stock in an underwritten public offering at $17.42 per share, which is equal to the closing price of the company's stock on the offering pricing date. Of the offered shares, about 5.8 million will be sold to certain MannKind officers and directors, including its chairman, CEO and principal stockholder, Alfred Mann, who will receive 5.75 million shares in the offering. The underwriters, which include JP Morgan Securities Inc. and Merrill Lynch & Co. as joint lead managers, and Wachovia Capital Markets LLC, CIBC World Markets Corp. and Leerink Swann & Co. Inc. as co-managers, have an overallotment option for an additional 3 million shares. Concurrent with the offering, MannKind is selling $100 million in 3.75 percent senior convertible notes due in 2013.

• Ondine Biopharma Corp., of Vancouver, British Columbia, issued an additional 462,000 shares priced at $1.60 each for proceeds of $740,000 to an underwriting group led by Canaccord Capital Corp., which exercised a portion of an overallotment option granted in connection to the company's recent public offering. Total gross proceeds to Ondine are $10.7 million. Funds will be used for the marketing and commercialization of Periowave in Canada and Europe and in the U.S., subject to approval, as well as for research and development and for general corporate purposes.

No Comments